| Document |
Document Title |
|
WO/2018/140578A1 |
Described herein are molecules for use in organic photovoltaic devices. Example molecules comprise at least one core moiety, two spacer moieties, and two terminal moieties. Values and preferred values of the core, spacer, and terminal mo...
|
|
WO/2018/137614A1 |
Disclosed are a heteroarothiadiazide-2,2-dioxide derivative, and a preparation method therefor and an application thereof in medicament. Specifically, disclosed are a novel heteroarothiadiazide-2,2-dioxide derivative represented by formu...
|
|
WO/2018/136890A1 |
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...
|
|
WO/2018/136265A1 |
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
|
|
WO/2018/130863A1 |
The invention relates to promoting authopagy in the treatment or prevention of autophagy related disorders, such as various forms of cancer; neurodegenerative disease, diabetes, immune deficiency, infection by intracellular microbes, tis...
|
|
WO/2018/127526A2 |
The present invention relates to novel solid forms of compound (I) [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidi
n-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid f...
|
|
WO/2018/127525A1 |
The present invention relates to a process for synthesizing a compound of formula (I), R1 is H or C1-6alkyl; R2 is H or hydroxy; or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis and treatment o...
|
|
WO/2018/123207A1 |
The purpose of the present invention is to provide a naphthobischalcogenadiazole derivative which can be used as an intermediate for producing a naphthobischalcogenadiazole compound having a fluorine atom introduced therein. The naphthob...
|
|
WO/2018/121267A1 |
A [1,3]thiazol-2-amine compound, an application, and a pharmaceutical composition. The present invention belongs to the field of BACE inhibitors. The [1,3]thiazol-2-amine compound is a compound represented by formula (I), or a pharmaceut...
|
|
WO/2018/119221A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2018/119266A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2018/073838A9 |
The present invention relates to a pyridinium oxazole dyad scaffold of formula (I) and a process for the preparation thereof. The present invention further discloses a pyridine compound of formula (II) which is used for the preparation o...
|
|
WO/2018/113538A1 |
The present invention relates to an organic compound with homobenzene as a core and the use thereof in an OLED device. The compound of the present invention has a higher glass transition temperature, a higher molecular heat stability, ap...
|
|
WO/2018/119263A1 |
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...
|
|
WO/2018/118598A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of FLT3 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Linda...
|
|
WO/2018/119183A2 |
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
|
|
WO/2018/116072A1 |
The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compo...
|
|
WO/2018/108070A1 |
A compound comprises a donor and an acceptor, wherein at least one donor ( "D" ) and at least one acceptor ( "A" ) may be arranged in an order of D-A; D-A-D; A-D-A; D-D-A-D-D; A-A-D-A-A; D-A-D-A-D; and A-D-A-D-A. The compound may be sele...
|
|
WO/2018/112084A1 |
The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): (Formula (I)) wherein variables X, Y, R2, R3, R4, R5, R6, and n of For...
|
|
WO/2018/112094A1 |
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are def...
|
|
WO/2018/103058A1 |
Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').
|
|
WO/2018/095839A1 |
The present invention relates to bridged triarylamines according to a defined formula. Said compounds are suitable for use in electronic devices. The invention also relates to methods for preparing said compounds and to electronic device...
|
|
WO/2018/096159A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmace...
|
|
WO/2018/093974A1 |
Amines and amine derivatives that improve the buffering range, and / or reduce the chelation and other negative interactions of the buffer and the system to be buffered. Aminopyridines channel blocking, combined with buffering and zwitte...
|
|
WO/2018/090921A1 |
Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds...
|
|
WO/2018/087126A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful ...
|
|
WO/2018/090045A1 |
An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, whi...
|
|
WO/2018/084141A1 |
The production of agricultural and horticultural crops, etc. is still seriously damaged by insect pests and the like and there are causative factors such as the appearance of insect pests resistant to the conventional chemicals. Under th...
|
|
WO/2018/083213A1 |
A preparation process of edoxaban tosylate monohydrate comprising dissolvingedoxaban free base, p-toluensulfonic acid in an appropriate amount of ACN/H2O and in an appropriate volume ratio, followed by crystallizing the product from ACN/...
|
|
WO/2018/081612A1 |
Substituted hydrazone compounds, methods of making such compounds and metal complexes thereof, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds and metal complexes to treat, preve...
|
|
WO/2018/078005A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I) : in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful...
|
|
WO/2018/077944A2 |
The present invention provides triazolone compounds compounds of general formula (I) : (I), in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, 5 intermediate compounds useful for preparing said com...
|
|
WO/2018/075332A1 |
Functionally altered biological mechanisms arising from disease-associated polymorphisms remain difficult to characterize when those variants are intergenic, or, fall between genes. The present invention uses computational modelling of s...
|
|
WO/2018/073602A1 |
The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
|
|
WO/2018/075339A1 |
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula (I):or a pharmaceutically acce...
|
|
WO/2018/069468A1 |
The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors,and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic d...
|
|
WO/2018/068017A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1...
|
|
WO/2018/065529A1 |
Provided are novel crystalline forms of a spiro-compoundwhich acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8- methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are describ...
|
|
WO/2018/065350A1 |
The invention relates to novel organic semiconducting compounds containing apolycyclicunit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to t...
|
|
WO/2018/059216A1 |
Disclosed are compounds reducing SAICAR synthase activity, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain c...
|
|
WO/2018/055135A1 |
A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally effective amount of a compound of Formula (I) wherein the substituents are as defined in claim 1, is applied to ...
|
|
WO/2018/055048A1 |
The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused...
|
|
WO/2018/050584A1 |
The invention relates to spirobifluorene derivatives which are substituted with electrone transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to t...
|
|
WO/2018/050583A1 |
The present invention relates to carbazole derivatives which are substituted with electron transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to ...
|
|
WO/2018/053157A1 |
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a pat...
|
|
WO/2018/041768A1 |
The invention relates to novel organic semiconducting (OSC) compounds containing one or more 1,3-dithiolo[5,6-f]benzo-2,1,3-thiadiazole ("DTBTz") or 1,3-dithiolo[6,7-g]quinoxaline ("DTQ") units or derivatives thereof, to methods for thei...
|
|
WO/2018/035005A1 |
The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3 and R5 are as defined herein. The present invention also relates...
|
|
WO/2018/034977A1 |
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula or a pharmaceutically acceptab...
|
|
WO/2018/033086A1 |
Disclosed are a compound having xanthone as the core and applications thereof in an organic electroluminescent component. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking m...
|
|
WO/2018/031334A1 |
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
|
